ADIL 1.05 Adial Pharmaceuticals, Inc.
| Range: | 0.77-4.17 | Vol Avg: | 2741125 | Last Div: | 0 | Changes: | 0.04 |
| Beta: | 1.3 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jul 27 2018 | Empoloyees: | 4 | ||
| CUSIP: | 00688A106 | CIK: | 0001513525 | ISIN: | US00688A2050 | Country: | US |
| CEO: | Mr. Cary John Claiborne MBA | Website: | https://www.adialpharma.com | ||||
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow